The pharmaceutical industry, a popular target for mass tort litigation, has repeatedly felt the sting of multimillion-dollar verdicts. As the recent Vioxx litigation demonstrates, one area in which the industry particularly needs to strengthen its defense position involves clinical trial protocols and implementation.

Understanding the key issues underlying these adverse verdicts for defendants, as well as developing and implementing appropriate information technology to address those issues, will facilitate standardization of clinical trial protocols and ensure a more rigorous and accurate reporting system companywide. Addressing critical issues related to the Vioxx litigation and improving clinical trial protocols and reporting will enable pharmaceutical companies to better manage risk in the pharmaceutical litigation arena.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]